Novo Nordisk announced positive Phase 3 trial results for CagriSema, a once-weekly therapy combining an amylin analog with a GLP-1 receptor agonist, which significantly reduced HbA1c and body weight in adults with Type 2 diabetes. The company also shared Phase 2 data for zenagamtide, showing dose-dependent improvements in blood sugar and weight loss, with plans to start Phase 3 trials in late 2026. Additionally, Novo Nordisk reported that Wegovy (semaglutide) tablets surpassed three million prescriptions within five months of launch, highlighting strong market demand. These developments reinforce Novo Nordisk's leadership in diabetes and weight management treatments, with further growth potential ahead.
The European Commission has approved Novo Nordisk's Wegovy pill, the first oral GLP-1 receptor agonist for weight management across the EU. This approval covers adults with obesity or overweight with related health issues and follows positive clinica...
The global blood glucose monitoring system market, valued at $16.8 billion in 2025, is projected to grow to $39.4 billion by 2035 at an 8.9% CAGR. Growth is fueled by rising diabetes prevalence, advancements in AI-enabled monitoring devices, and incr...
Vivani Medical is developing a semaglutide implant aimed at improving long-term adherence to GLP-1 treatments like Wegovy and Ozempic, which help with obesity and diabetes. The implant, designed to be replaced biannually or annually, could reduce sid...
